Aficamten
Aficamten is the medicine in Myqorzo, a tablet. The US label calls it a cardiac myosin inhibitor, and says it is an allosteric and reversible inhibitor of cardiac myosin motor activity. The label gives its indication as symptomatic obstructive hypertrophic cardiomyopathy in adults, to improve functional capacity and symptoms. A boxed warning says it reduces left ventricular ejection fraction and can cause heart failure, and that it is available only through a restricted program. The atlas holds no trial results for it.
Also called Myqorzo
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 2731469; the label UNII B1I77MH6K1 equals the ingredient's. MeSH has no descriptor for aficamten (an exact-label lookup returned an empty list on 2026-11-19). RxClass returned no FDA class for the ingredient (empty answer, hash only), so the class wording comes from the label, which calls the product a cardiac myosin inhibitor; RxClass gives mavacamten the established pharmacologic class Cardiac Myosin Inhibitor. The atlas has no page for that class, so the record files under the medicines front and links to mavacamten. The label read is the Cytokinetics Inc. label for Myqorzo, application NDA219083, effective 2025-12-16 in openFDA; it is the only openFDA label returned for the ingredient, and Drugs@FDA lists one application with four tablet strengths. This page records the label indication, the boxed-warning title and two statements, and the mechanism sentence only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says aficamten is an allosteric and reversible inhibitor of cardiac myosin motor activity; it reduces the force generated by myosin at the cardiac sarcomere.
Claims and evidence
Context Adults with symptomatic obstructive hypertrophic cardiomyopathy, as described in the US label of Myqorzo
- Recipient
- Recipient not specified
- Population
- Adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), as the indications section of the label describes them. The passages read give no other age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
- Excluded
- None stated
The US label of Myqorzo (aficamten tablets; Cytokinetics Inc., application NDA219083; the version dated 2025-12-16 in openFDA) calls the product a cardiac myosin inhibitor. It lists the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy, to improve functional capacity and symptoms, as the indication.
Applies to Recipient not specified Adults with symptomatic obstructive hypertrophic cardiomyopathy, as described in the US label of Myqorzo
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the atlas holds no trial result for it. The label also gives a boxed warning, recorded in a separate claim. Contraindications, other warnings, interactions, the pregnancy, lactation and pediatric sections and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-19
- Next evidence check due
- Not scheduled
Sources and citations (5)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA219083.
- Retrieved
- Source effective date
- 2025-12-16
- Source state
- Current
- Version fingerprint
f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20251216.
- Retrieved
- Source effective date
- 2025-12-16
- Source state
- Current
- Version fingerprint
f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], highlights sentence
- How it applies
- Label passage quoted in the research quote table (Q-W4K28-AFI-LB-04).
- Retrieved
- Source effective date
- 2025-12-16
- Source state
- Current
- Version fingerprint
f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], indication statement
- How it applies
- Label passage quoted in the research quote table (Q-W4K28-AFI-LB-05).
- Retrieved
- Source effective date
- 2025-12-16
- Source state
- Current
- Version fingerprint
f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], indication statement, purpose
- How it applies
- Label passage quoted in the research quote table (Q-W4K28-AFI-LB-06).
- Retrieved
- Source effective date
- 2025-12-16
- Source state
- Current
- Version fingerprint
f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Patients treated with aficamten, as described in a US Myqorzo label boxed warning about heart failure
- Recipient
- Recipient not specified
- Population
- Patients who take the medicine, as the boxed warning describes the risk: the warning concerns heart failure due to systolic dysfunction in people treated with it. The passages read give no age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients treated with the medicine (adults with symptomatic obstructive hypertrophic cardiomyopathy, per the indication)
- Excluded
- None stated
The same US label carries a boxed warning titled risk of heart failure. It says the medicine "reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction", and that, because of this risk, it "is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS)".
Applies to Recipient not specified Patients treated with aficamten, as described in a US Myqorzo label boxed warning about heart failure
- Certainty method
- Not assessed
- Limitations
- This claim records the boxed-warning title and two statements only. The warning also gives instructions about heart-ultrasound checks, ejection-fraction thresholds and stopping or changing treatment; those are the label's, are not repeated here and are not advice. Other warnings, contraindications and interactions were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-19
- Next evidence check due
- Not scheduled
Sources and citations (5)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA219083.
- Retrieved
- Source effective date
- 2025-12-16
- Source state
- Current
- Version fingerprint
f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20251216.
- Retrieved
- Source effective date
- 2025-12-16
- Source state
- Current
- Version fingerprint
f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], title
- How it applies
- Label passage quoted in the research quote table (Q-W4K28-AFI-LB-08).
- Retrieved
- Source effective date
- 2025-12-16
- Source state
- Current
- Version fingerprint
f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], first sentence
- How it applies
- Label passage quoted in the research quote table (Q-W4K28-AFI-LB-09).
- Retrieved
- Source effective date
- 2025-12-16
- Source state
- Current
- Version fingerprint
f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], restricted program sentence
- How it applies
- Label passage quoted in the research quote table (Q-W4K28-AFI-LB-10).
- Retrieved
- Source effective date
- 2025-12-16
- Source state
- Current
- Version fingerprint
f2cdd5f6f5ff3fae7c8bba98d3750fe0a2b5d12f05156704cef67bf6861c251c- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists symptomatic obstructive hypertrophic cardiomyopathy in adults, to improve functional capacity and symptoms, as an indication: Hypertrophic cardiomyopathy
Applies to Recipient not specified Adults with symptomatic obstructive hypertrophic cardiomyopathy, as described in the US label of Myqorzo
The US label of Myqorzo (aficamten tablets; Cytokinetics Inc., application NDA219083; the version dated 2025-12-16 in openFDA) calls the product a cardiac myosin inhibitor. It lists the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy, to improve functional capacity and symptoms, as the indication.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the atlas holds no trial result for it. The label also gives a boxed warning, recorded in a separate claim. Contraindications, other warnings, interactions, the pregnancy, lactation and pediatric sections and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:aficamten- Content hash
ea828d1641110e5cc6efeb1025faaa6af4c40716bdd42b15b4790e92981f53c6